anlotinib+CAPEOX/SOX
PreclinicalSmall molecule
anlotinib+CAPEOX/SOX is one of 10 small molecule programs targeting Adjuvant Treatment. It is currently in Preclinical.
1
Indications
1
Total Trials
1
Active Trials
9
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
9 competitors in Adjuvant Treatment
#DrugCompanyPhaseTrials
1Herceptin
OOrganon and Co
Phase 3
Vermox
WWim Janssens
Phase 3
Keytruda
Merck & Co.Phase 2
Amrix
TTonix Pharmaceuticals, Inc.
Phase 3
Lenvima
EisaiPhase 2
Alecensa
RochePhase 2
Beyfortus
BeiGenePhase 2
Serplulimab
Shanghai Henlius BiotechPhase 2
Sintilimab Plus Chemotherapy
FFudan University
Phase 2
anlotinib+CAPEOX/SOX
XXijing Hospital
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for anlotinib+CAPEOX/SOX. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- XXijing Hospital